AKT1 and intestinal cancer: Administration of EGCG into intestinal cancer mouse model led to elevation of E-cadherin protein levels and decrease of protein levels of c-Myc, nuclear β-catenin, protein kinase B, and ERK1/2, indicating that EGCG inhibits intestinal tumorigenesis through suppression of the AKT and ERK signaling cascade [243].